Biological nanoparticle-derived exosome for improving osteoarthritis and application thereof

High-quality biological nanoparticle-derived exosomes are prepared by specific cell culture and exosome separation methods, and combined with microspheres to achieve slow release in vivo, solving the poor effect of exosome application in the prior art Problem, significantly improving the symptoms and disease progression of osteoarthritis.

CN119082002APending Publication Date: 2024-12-06LIANYUNGANG SECOND PEOPLES HOSPITAL (LIANYUNGANG CLINICAL TUMOR RES INST)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411234745.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art has poor application effect on improving osteoarthritis, especially the lack of preparation methods and delivery systems, resulting in limited therapeutic effects.

Method used

High-quality biological nanoparticle-derived exosomes were prepared by specific cell culture and exosome separation methods, and combined with microspheres. A microfluidic device was used to form uniformly sized liquid droplets and cross-linked by ultraviolet irradiation , combined with polydopamine surface modification, achieves slow release in the body.

Benefits of technology

It significantly reduces oxidative stress in chondrocytes, increases the expression of extrachondrocyte matrix, effectively relieves the symptoms of osteoarthritis, significantly retains the expression of glycosaminoglycans in articular cartilage, and alleviates disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082002A_ABST
    Figure CN119082002A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological nano-particle exosomes, and discloses a biological nano-particle derived exosome for improving osteoarthritis and application of the biological nano-particle derived exosome. A cell culture step: separating cartilage cells from cartilage of the 8-week-old mouse, culturing in a DMEM / F12 culture medium containing 10% of fetal calf serum, then digesting in a DMEM / F12 culture medium containing 2 mg / mL of type II collagenase, performing centrifugal treatment on the digested cells, and then culturing; and an exosome separation step: separating the exosome from the third-generation to sixth-generation mouse synovial fibroblasts subjected to the treatment, centrifuging the cell culture supernatant, centrifuging the supernatant, washing particles with PBS to remove pollutants, centrifuging again, and resuspending with PBS. According to the invention, through specific cell culture and exosome separation methods, the biological nanoparticle-derived exosome with high quality and high activity for improving osteoarthritis is prepared.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biological nanoparticle exosomes, and in particular to biological nanoparticle-derived exosomes for improving osteoarthritis and applications thereof. Background Art

[0002] Osteoarthritis is a common and widespread degenerative joint disease that has a serious negative impact on the quality of life of patients. Currently, traditional treatments for osteoarthritis mainly include medication to relieve symptoms, physical therapy, and surgical intervention in severe cases. However, these methods can often only relieve pain and improve joint function to a certain extent, and have limited effects on preventing the progression of the disease and promoting the repair of damaged articular cartilage.

[0003] Oxidative stress plays a key role in the pathophysiological process of osteoarthritis. Oxidative stress can lead to direct degradation of the extracellular matrix of cartilage cells, destroying key components such as collagen and proteoglycans that maintain the structural integrity and function of cartilage. This not only reduces the thickness and elasticity of cartilage, causing joint pain and stiffness, but also disrupts the balance of anabolism and catabolism in the joint, inhibits the synthesis of matrix components, and promotes the expression of catabolic factors, further accelerating the degradation of cartilage and hindering its own repair mechanism.

[0004] Synovial tissue plays an important role in the development of osteoarthritis. The synovium lines the inner surface of the joint capsule and not only secretes synovial fluid to lubricate the joint, but also provides the necessary nutrients and growth factors for the articular cartilage, thereby maintaining the health and function of the cartilage under normal conditions. When osteoarthritis occurs, the synovium releases pro-inflammatory cytokines and enzymes, which further aggravate the degradation of cartilage and promote the development of joint inflammation, forming a vicious cycle and aggravating the symptoms of osteoarthritis.

[0005] Exosomes, as key mediators of intercellular communication, are secreted by cells into the extracellular environment and carry a variety of bioactive substances, such as proteins, nucleic acids, etc. In the field of biomedicine, exosomes have potential therapeutic applications, especially in tissue repair and regeneration. However, the existing research and application of exosomes in improving osteoarthritis are still insufficient. On the one hand, there is a lack of optimization of the source and preparation methods of exosomes, resulting in less than ideal results in the treatment of osteoarthritis; on the other hand, there is a lack of effective delivery systems to ensure that exosomes can accurately reach the site of joint lesions and continue to play a role.

[0006] Therefore, there is an urgent need to develop new bio-nanoparticle-derived exosomes and their application methods to more effectively improve the symptoms of osteoarthritis and delay the progression of the disease, providing an innovative and more promising solution for the treatment of osteoarthritis. Summary of the invention

[0007] 1. Technical issues to be resolved In view of the deficiencies of the prior art, the present invention provides a bio-nanoparticle-derived exosome for improving osteoarthritis and applications thereof.

[0008] (II) Technical solution A method for preparing biological nanoparticle-derived exosomes for improving osteoarthritis: Cell culture steps: Cultured mouse synovial fibroblasts, whose origin was limited to Hycyte, were treated with 100 nM of SOD3 mimetic control substances; Chondrocytes were isolated from the cartilage of 8-week-old mice and cultured in DMEM / F12 medium containing 10% fetal bovine serum. The chondrocyte isolation process was to cut the cartilage into 1 mm pieces using a sterile blade. 3 The fragments were then digested in DMEM / F12 medium containing 2 mg / mL type II collagenase Thermo for 6 h, and the digested cells were centrifuged before culturing; Exosome isolation steps: Exosomes were isolated from 3-6 passage mouse synovial fibroblasts treated as described above. 7 The cell culture supernatant was centrifuged at 300 g for 10 min to remove cells and 3000 g for 15 min to discard cell debris. The supernatant was then centrifuged at 120,000 g for 1 h, the pellet was washed with PBS to remove contaminants, and finally centrifuged again at 120,000 g for 70 min. The purified pellet was resuspended in 200 µL PBS and stored at -80°C.

[0009] Preferably, the exosomes have a round convex structure, and their particle size range is determined to be a specific interval by nanoparticle tracking analysis; Western blotting showed that the exosome markers CD9, CD63, and TSG101 were positively labeled, and the SOD3 content in the exosomes derived from synovial fibroblasts treated with SOD3 mimics was significantly higher than that in the exosomes derived from synovial fibroblasts treated with the control.

[0010] Preferably, the exosomes are used in the preparation of drugs or medical devices for treating osteoarthritis; In vitro applications: Chondrocytes were stimulated with 10 ng / mL IL-1β and treated with 10 µg / mL exosomes to detect the levels of mitoROS and reactive oxygen species (ROS), the expression of chondrocyte ECM synthesis-related genes Col2a1 and ACAN, and the expression of matrix degradation-related genes Mmp13 and Adamts5; In vivo applications: In the established mouse OA model, after the mice were specifically treated by surgery, microspheres containing the exosomes of the present invention were injected into the joints every two weeks to detect the expression levels of articular cartilage glycosaminoglycans, SOD3 and ACAN.

[0011] Preferably, when preparing microspheres containing exosomes, the following steps and parameters are used: The raw materials for preparing microspheres included 10 wt% GelMA, photoinitiator, and 5 wt% Span80 oil, which were processed in a microfluidic device to form droplets of uniform size, and the droplets were cross-linked by ultraviolet irradiation; The synthesized microspheres were washed with 75% ethanol solution and stored in deionized water; For surface modification, the microspheres were immersed in a polydopamine (PDA) solution (2 mg / mL in 10 mM Tris-HCl, pH 8.5) for 6 h to form modified microspheres with specific properties and functions.

[0012] 3. Beneficial technical effects The present invention prepares high-quality and high-activity biological nanoparticle-derived exosomes for improving osteoarthritis through specific cell culture and exosome separation methods.

[0013] The present invention significantly reduces the levels of mitoROS and ROS in chondrocytes by applying the exosomes in in vitro cell experiments, prevents oxidative stress from damaging chondrocytes, increases the expression of key components of the extracellular matrix of chondrocytes, upregulates genes related to ECM synthesis, and reduces the expression of genes related to matrix degradation.

[0014] The present invention combines exosomes with specific microsphere preparation technology, and achieves effective delivery and slow release of exosomes in joints in an in vivo experiment of a mouse OA model, significantly retains the expression of glycosaminoglycans in articular cartilage, increases the expression of the key protein SOD3, and effectively alleviates the severity of osteoarthritis.

[0015] Through the above innovative design and application methods, the present invention provides a new, multi-faceted and effective solution for the treatment of osteoarthritis, which is expected to play an important role in clinical applications, improve the quality of life of patients and reduce the social medical burden. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 Figure 3 is a diagram of the preparation process of superoxide dismutase 3-enriched exosomes (S-EXOs).

[0017] Figure 2 This is a diagram of the preparation process of hydrogel microspheres containing S-Exos.

[0018] Figure 3 This is a diagram of the process of intra-articular injection of hydrogel microspheres loaded with S-EXOs to treat osteoarthritis.

[0019] Figure 4 Western blot analysis of ex= and S-EXOs specific protein marker 3. (=-e) Figure 5 is the effect of EXOs and S-EXOs on the amount of mitoROS (red) and intracellular ROS (green) in chondrocytes.

[0020] Figure 6 is the mitoROS intensity map.

[0021] Figure 7 is a graph of ROS intensity.

[0022] Figure 8 This is the expression of glycosaminoglycans after intra-articular injection of microspheres.

[0023] Fig. 9 is the immunofluorescence image of ACAN expression.

[0024] Fig.10 It is the immunofluorescence image of MMP13 expression.

[0025] Fig.11 This is a graph of Col2a1 mRNA expression analyzed by RT-PCR.

[0026] Fig.12 This is a graph of Acan mRNA expression analyzed by RT-PCR.

[0027] Fig.13 This is a graph of MMP13 mRNA expression analyzed by RT-PCR.

[0028] Fig.14 This is a graph of Adamts5 mRNA expression analyzed by RT-PCR. DETAILED DESCRIPTION Example 1

[0029] Cell culture steps: Cultured mouse synovial fibroblasts, whose origin was limited to Hycyte, were treated with 100 nM of SOD3 mimetic control substances; Chondrocytes were isolated from the cartilage of 8-week-old mice and cultured in DMEM / F12 medium containing 10% fetal bovine serum. The chondrocyte isolation process was to cut the cartilage into 1 mm pieces using a sterile blade. 3 The fragments were then digested in DMEM / F12 medium containing 2 mg / mL type II collagenase Thermo for 6 h, and the digested cells were centrifuged before culturing; Exosome isolation steps: Exosomes were isolated from 3-6 passage mouse synovial fibroblasts treated as described above. 7 The cell culture supernatant was centrifuged at 300 g for 10 min to remove cells and 3000 g for 15 min to discard cell debris. The supernatant was then centrifuged at 120,000 g for 1 h, the pellet was washed with PBS to remove contaminants, and finally centrifuged again at 120,000 g for 70 min. The purified pellet was resuspended in 200 µL PBS and stored at -80°C. Example 2

[0030] Western Blotting: Proteins were separated using RIPA lysis buffer (Beyotime) containing protease inhibitors. The concentration of protein samples was detected using a BCA kit (Beyotime). Equal amounts of protein were electrophoresed on a 10% SDS-PAGE gel and then transferred to a nitrocellulose membrane. After blocking at room temperature for 1 hour, the membrane was incubated with the primary antibody overnight at 4°C. The antibodies used were COL II (Abcam, ab188570), ACAN (ACAN, ab315486), MMP13 (Abcam, ab39012), ADAMTS5 (Abcam, ab41037), β-actin (Ab8226), CD9 (CST, 98, 327S), CD63 (Immune Pathway, YT5525), SOD3 (Santa, 271, 170), 3 (Immune Pathway, YT5525), SOD3 (Santa, 271, 170), calnexin (Affinity, AF5362) and TSG101 (Abcam, ab125011). The following day, the cell membranes were incubated with HRP-conjugated secondary antibodies (Abcam, ab6721 or ab6788) at room temperature for 1 hour. A highly sensitive chemiluminescent substrate (Beyotime) was used for detection, and β-actin was used as a loading control to quantitatively analyze the optical density (OD) value.

[0031] Western blotting showed that the exosome markers CD9, CD63, and TSG101 were positively labeled, and the SOD3 content in the exosomes derived from synovial fibroblasts treated with SOD3 mimics was significantly higher than that in the exosomes derived from synovial fibroblasts treated with the control. Example 3

[0032] In vitro applications: In the in vitro cell experiment, when chondrocytes were stimulated with 10 ng / mL of IL-1β, after the addition of exosomes (10 µg / mL) treatment, compared with chondrocytes stimulated with IL-1β alone, the levels of mitoROS and ROS were significantly reduced. At the same time, the expression of ACAN, a key component of ECM, was significantly increased, the expression of ECM synthesis-related genes Col2a1 and ACAN was upregulated, and the expression of matrix degradation-related genes Mmp13 and Adamts5 was reduced. RT-PCR was used for analysis.

[0033] In vivo applications: In the established mouse OA model, after the mice were specifically treated by surgery, microspheres containing the exosomes of the present invention were injected into the joints every two weeks. Compared with mice not treated with exosomes or treated with other controls, more glycosaminoglycan expression in the articular cartilage was significantly retained, and the expression of SOD3 and ACAN in the cartilage was increased, which was measured by immunofluorescence.

[0034] The raw materials for preparing microspheres included 10wt% GelMA, photoinitiator and 5wt% Span80 oil, which were processed in a microfluidic device to form droplets of uniform size, and the droplets were cross-linked by ultraviolet irradiation; The synthesized microspheres were washed with 75% ethanol solution and stored in deionized water; For surface modification, the microspheres were immersed in a polydopamine (PDA) solution, 2 mg / mL, in 10 mM Tris-HCl, pH 8.5, for 6 hours to form modified microspheres with specific properties and functions.

[0035] The preferred embodiments of the present invention disclosed above are only used to help illustrate the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the invention to the specific implementation methods described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.

[0036] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for preparing biological nanoparticle-derived exosomes for improving osteoarthritis, characterized in that: The preparation method is as follows: Cell culture steps: Cultured mouse synovial fibroblasts, whose origin was limited to Hycyte, were treated with 100 nM of SOD3 mimetic control substances; Chondrocytes were isolated from the cartilage of 8-week-old mice and cultured in DMEM / F12 medium containing 10% fetal bovine serum. The chondrocyte isolation process was to cut the cartilage into 1 mm pieces using a sterile blade. 3 The fragments were then digested in DMEM / F12 medium containing 2 mg / mL type II collagenase Thermo for 6 h, and the digested cells were centrifuged before culturing; Exosome (EXOs) isolation steps: Exosomes were isolated from 3-6 passage mouse synovial fibroblasts treated as described above. 7 The cell culture supernatant was centrifuged at 300 g for 10 min to remove cells and 3000 g for 15 min to discard cell debris. The supernatant was then centrifuged at 120,000 g for 1 h, the pellet was washed with PBS to remove contaminants, and finally centrifuged again at 120,000 g for 70 min. The purified pellet was resuspended in 200 µL of PBS and stored at -80°C.

2. The method for preparing biological nanoparticle-derived exosomes for improving osteoarthritis according to claim 1, characterized in that: The exosomes have a round convex structure, and their particle size range is determined to be a specific interval by nanoparticle tracking analysis; Western blotting showed that the exosome markers CD9, CD63, and TSG101 were positively labeled, and the SOD3 content in the exosomes derived from synovial fibroblasts treated with superoxide dismutase 3 (SOD3) mimics was significantly higher than that in the exosomes derived from synovial fibroblasts treated with the control.

3. The use of exosomes prepared by the method for preparing biological nanoparticle-derived exosomes for improving osteoarthritis according to claim 1 or 2, characterized in that: Use of the exosomes in preparing drugs or medical devices for treating osteoarthritis; In vitro applications: Chondrocytes were stimulated with 10 ng / mL IL-1β and treated with 10 µg / mL exosomes to detect the levels of mitochondrial reactive oxygen species mitoROS and reactive oxygen species ROS, the expression of chondrocyte ECM synthesis-related genes Col2a1 and ACAN, and the expression of matrix degradation-related genes Mmp13 and Adamts5; In vivo applications: In the established mouse OA model, after the mice were specifically treated by surgery, microspheres containing the exosomes of the present invention were injected into the joints every two weeks to detect the expression levels of articular cartilage glycosaminoglycans, SOD3 and ACAN.

4. The use of exosomes prepared by the method for preparing biological nanoparticle-derived exosomes for improving osteoarthritis according to claim 3, characterized in that: The following steps and parameters were used to prepare microspheres containing exosomes: The raw materials for preparing microspheres included 10 wt% GelMA, photoinitiator, and 5 wt% Span80 oil, which were processed in a microfluidic device to form droplets of uniform size, and the droplets were cross-linked by ultraviolet irradiation; The synthesized microspheres were washed with 75% ethanol solution and stored in deionized water; For surface modification, the microspheres were immersed in a polydopamine (PDA) solution: 2 mg / mL in 10 mM Tris-HCl, pH 8.5, for 6 hours to form modified microspheres with specific properties and functions.